Innovative Diagnostic Platform Epic Sciences specializes in liquid biopsy technology for detecting genetic and molecular changes in cancer, making their offerings valuable for healthcare providers seeking non-invasive, real-time diagnostics to improve personalized treatment strategies.

Strategic Industry Partnerships Having established collaborations with leading pharmaceutical companies and top cancer centers worldwide, Epic Sciences presents opportunities for partners seeking cutting-edge diagnostic solutions that enhance clinical trial success rates and patient management.

Recent Funding Growth With a Series G funding round of $24 million led by notable investors like Arsenal Capital Partners and Deerfield Management, Epic Sciences demonstrates strong financial backing, supporting expansion into new markets and product development targeting oncology diagnostics.

Market Expansion Opportunities Epic's recent product launches, such as the DefineMBC blood test for metastatic breast cancer, indicate growth potential in specialized oncology diagnostics, appealing to medical laboratories, hospitals, and research institutions seeking innovative testing options.

Growth & Investment Trends With a substantial funding total of $92 million and a revenue range of $10M to $25M, Epic Sciences positions itself as a growth-focused company, creating prospects for sales teams to engage with biotech and healthcare organizations interested in advanced cancer detection technologies.